Following the guidance issued by the NIHR (link below), we are pausing the PRED4 study until further notice.
Thank you for your understanding at this extremely difficult time, the Exeter team are available via email to answer any queries you may have.
https://t.co/x5NcS7E80B
This is @PANTSresearch - collaborative UK IBD research at its best. Led tirelessly by @tariqahmadIBD + @ClaireBewshea ... driven by @DrNickKennedy + @alehins ... & many of us with brilliant sites & >1500 patients, prospective data and a gene hit of direct clinical utility.
The main treatment for #Crohns disease is a TNF-antibody, but many patients develop an immune response. It turns out that a common HLA allele (40% w/ European ancestry) is tied to this problem https://t.co/HlAMUZEGnB @AGA_Gastro@AmerGastroAssn#PGX
It has been a privilege to contribute to this enormous project, as well as adjudicate some arms, and be a part of the publications arising from PRED4. Tariq Ahmad changed the world of Pharmacogenetics in IBD.@CDDFTRnI
BRAVO @PRED4research Tariq & @ClaireBewshea - Not only transforming the pharmacogenetic landscape in #IBD, but also launching a vintage era for IBD research in the UK - collaborative, #bigdata projects - demonstrating what is possible with vision & grit on a shoestring.
... from 1st September 2019 as we now have enough recruits to the study we will be closing all arms except anti TNF induced skin reactions in IBD (ANTS) so please keep recruiting to ANTS! Thank you for your support 🧬😀
3000 patients 👩👩👦, 7 years 🗓️, 9 arms 🧬, 162 sites 🏥 later... thank you to all the patients, research nurses and PIs who have contributed to @pred4research....
First paper from PANTS, our UK-wide 1610-patient study of #antiTNF in #Crohns has been published online. Thanks to the patients, doctors, nurses & #research teams who made this possible! @gutsandgenes @RDEResearch @UniofExeter https://t.co/hnspUIpN8t